Jessie Hanrahan Net Worth

The estimated Net Worth of Jessie Hanrahan is at least $88.8 Mille dollars as of 2 December 2023. Jessie Hanrahan owns over 11,862 units of Solid Biosciences Inc stock worth over $88,846 and over the last 2 years Jessie sold SLDB stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jessie Hanrahan SLDB stock SEC Form 4 insiders trading

Jessie has made over 1 trades of the Solid Biosciences Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Jessie exercised 11,862 units of SLDB stock worth $88,846 on 2 December 2023.

The largest trade Jessie's ever made was exercising 11,862 units of Solid Biosciences Inc stock on 2 December 2023 worth over $88,846. On average, Jessie trades about 3,954 units every 0 days since 2022. As of 2 December 2023 Jessie still owns at least 11,862 units of Solid Biosciences Inc stock.

You can see the complete history of Jessie Hanrahan stock trades at the bottom of the page.

What's Jessie Hanrahan's mailing address?

Jessie's mailing address filed with the SEC is C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN, MA, 02129.

Insiders trading at Solid Biosciences Inc

Over the last 7 years, insiders at Solid Biosciences Inc have traded over $9,620,465 worth of Solid Biosciences Inc stock and bought 13,973,934 units worth $97,227,521 . The most active insiders traders include Advisors Llcperceptive Life..., Capital Management, L.P.Ra ... e Rajeev M. Shah. On average, Solid Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $1,822,871. The most recent stock trade was executed by Ian F Smith on 3 July 2024, trading 3,255 units of SLDB stock currently worth $24,380.

What does Solid Biosciences Inc do?

solid biosciences (solid) is a cambridge, ma based biotech company singularly focused on developing treatments and cures for duchenne muscular dystrophy (dmd). solid combines sharp commercial focus with world-class science to advance promising therapies and is positioned to catalyze therapeutic development across all aspects of the disease. condition-focused, our mandate is comprehensive; improving daily life for patients and attacking the roots of dmd.

Complete history of Jessie Hanrahan stock trades at Solid Biosciences Inc

Solid Biosciences Inc executives and stock owners

Solid Biosciences Inc executives and other stock owners filed with the SEC include:

• Carl Morris,
  Chief Scientific Officer
• Ilan Ganot,
  President, Chief Executive Officer, Co-Founder, Director
• Jennifer Ziolkowski,
  Chief Financial Officer, Treasurer
• Ilan Ganot,
  Co-founder, Pres, CEO & Director
• Dr. Carl Ashley Morris,
  Chief Scientific Officer
• Adam Koppel,
  Independent Director
• Lynne Sullivan,
  Independent Director
• Martin Freed,
  Independent Director
• Dr. Andrey Juan Zarur Ph.D.,
  Co-Founder
• Adam Stone,
  Independent Director
• Sukumar Nagendran,
  Independent Director
• Matthew Arnold,
  Independent Director
• Rajeev Shah,
  Independent Director
• Robert Huffines,
  Independent Director
• Ian F. Smith A.C.A., ACA, C.P.A., CPA,
  Exec. Chair
• Matthew Bennett Arnold,
  Co-Founder & Board Member
• Carlo Tanzi,
  IR Contact Officer
• Lynette Herscha,
  Chief Legal Officer and Secretary
• Joel Schneider,
  Chief Technology Officer and Head of Exploratory Research and Development
• Ian Smith,
  Chairman of the Board
• Gilad David Hayeem,
  Co-Founder
• Dr. Cathryn M. Clary M.B.A., M.D.,
  Acting Chief Medical Officer
• Erin Powers Brennan,
  Chief Legal Officer & Sec.
• Caitlin Lowie,
  VP of Communications & IR
• Stephen J. DiPalma M.B.A.,
  Treasurer & Principal Accounting Officer
• Dr. Joel Solomon Zev Schneider Ph.D.,
  Chief Operating Officer
• Michael Inbar CPA, M.B.A.,
  Sr. VP of Fin.
• Annie Ganot,
  Co-Founder & Director of Patient Advocacy
• Pedro Alvaro Amorrortu,
  Chief Operating Officer
• Jorge Armando Quiroz,
  Chief Medical Officer
• Capital Management, L.P.Ra ...,
  
• Advisors Llcperceptive Life...,
  
• Chase & Cojpmc Strategic In...,
  
• Advisors Llcedelman Joseph ...,
  
• Gilad David Hayeem,
  10% owner
• Juan Andrey Zarur,
  Director
• Kevin Tan,
  CFO & Treasurer
• Capital, Llc Boxer,
  10% owner
• Capital Management, L.P.Ra ...,
  
• Capital Life Sciences Inves...,
  
• Advisors Llcperceptive Life...,
  
• Capital Management, L.P.Ra ...,
  
• Jessie Hanrahan,
  Chief Regulatory Officer
• Erin Powers Brennan,
  Chief Legal Officer, Secretary
• Clare Kahn,
  
• Advisors Llcperceptive Life...,
  
• David T Howton,
  Chief Operating Officer
• Jennifer Marlowe,
  CSO
• Alexander Cumbo,
  President and CEO
• Paul Herzich,
  Chief Technology Officer
• Gabriel Brooks,
  Chief Medical Officer
• Georgia Keresty,